INTRODUCTION: Available data on women fertility for younger patients treated using RIC Allo-SCT are still limited. We evaluated ovarian function and fertility among female patients younger than 35 years who received RIC Allo-SCT for hematological malignancy or aplastic anemia (AA). PATIENTS AND METHODS: Information on therapies before RIC Allo-SCT were collected. Data on ovarian function and fertility evaluation after RIC Allo-SCT included clinical and biological criteria. Twenty-two patients were evaluated. RESULTS: After RIC Allo-SCT, amenorrhea affects 68.1% of patients. Ovarian function was impaired for 86.3% of cases. All 3 AA patients have regular cycles and became pregnant after RIC Allo-SCT. Only 6 (27.2%) patients declared to have been correctly informed before RIC Allo-SCT on potential deleterious effects on fertility of anticancer treatment and only 36.8% of patients with ovarian failure had a hormonal supplementation. CONCLUSION: Results showed a high rate of ovarian failure, evaluated by clinical and biological criteria. The difference between AA and malignant diseases might suggest that a potential deleterious role was played by previous anticancer treatments rather than by RIC Allo-SCT.
INTRODUCTION: Available data on women fertility for younger patients treated using RIC Allo-SCT are still limited. We evaluated ovarian function and fertility among female patients younger than 35 years who received RIC Allo-SCT for hematological malignancy or aplastic anemia (AA). PATIENTS AND METHODS: Information on therapies before RIC Allo-SCT were collected. Data on ovarian function and fertility evaluation after RIC Allo-SCT included clinical and biological criteria. Twenty-two patients were evaluated. RESULTS: After RIC Allo-SCT, amenorrhea affects 68.1% of patients. Ovarian function was impaired for 86.3% of cases. All 3 AA patients have regular cycles and became pregnant after RIC Allo-SCT. Only 6 (27.2%) patients declared to have been correctly informed before RIC Allo-SCT on potential deleterious effects on fertility of anticancer treatment and only 36.8% of patients with ovarian failure had a hormonal supplementation. CONCLUSION: Results showed a high rate of ovarian failure, evaluated by clinical and biological criteria. The difference between AA and malignant diseases might suggest that a potential deleterious role was played by previous anticancer treatments rather than by RIC Allo-SCT.
Authors: A Balduzzi; J-H Dalle; K Jahnukainen; M von Wolff; G Lucchini; M Ifversen; K T Macklon; C Poirot; T Diesch; A Jarisch; D Bresters; I Yaniv; B Gibson; A M Willasch; R Fadini; L Ferrari; A Lawitschka; A Ahler; N Sänger; S Corbacioglu; M Ansari; R Moffat; A Dalissier; E Beohou; P Sedlacek; A Lankester; C D De Heredia Rubio; K Vettenranta; J Wachowiak; A Yesilipek; E Trigoso; T Klingebiel; C Peters; P Bader Journal: Bone Marrow Transplant Date: 2017-07-24 Impact factor: 5.483
Authors: R Phelan; E Mann; C Napurski; T E DeFor; A Petryk; W P Miller; J E Wagner; M R Verneris; A R Smith Journal: Bone Marrow Transplant Date: 2016-06-06 Impact factor: 5.483
Authors: J-H Dalle; G Lucchini; A Balduzzi; M Ifversen; K Jahnukainen; K T Macklon; A Ahler; A Jarisch; M Ansari; E Beohou; D Bresters; S Corbacioglu; A Dalissier; C Diaz de Heredia Rubio; T Diesch; B Gibson; T Klingebiel; A Lankester; A Lawitschka; R Moffat; C Peters; C Poirot; N Saenger; P Sedlacek; E Trigoso; K Vettenranta; J Wachowiak; A Willasch; M von Wolff; I Yaniv; A Yesilipek; P Bader Journal: Bone Marrow Transplant Date: 2017-03-13 Impact factor: 5.483
Authors: Filip Pirsl; Lauren M Curtis; Seth M Steinberg; Sri Harsha Tella; Mašenjka Katić; Marnie Dobbin; Jennifer Hsu; Fran T Hakim; Jacqueline W Mays; Annie P Im; Dražen Pulanić; Sandra A Mitchell; Judy Baruffaldi; Licia Masuch; David C Halverson; Ronald E Gress; Julianna Barsony; Steven Z Pavletic Journal: Biol Blood Marrow Transplant Date: 2016-04-23 Impact factor: 5.742
Authors: Sharrόn L Manuel; Molly B Moravek; Rafael Confino; Kristin N Smith; Angela K Lawson; Susan C Klock; Mary Ellen Pavone Journal: J Assist Reprod Genet Date: 2019-12-11 Impact factor: 3.412